# US 2022/0017534 A1 · In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017534 A1
- Document ID: US20220017534A1
- Status: Published application
- Kind: A1
- Application number: 17/309,259
- Filed: 2019-11-12
- Published: 2022-01-20
- Earliest claimed: 2018-11-12
- Assignees: University of Virginia Patent Foundation
- Applicants: University of Virginia Patent Foundation
- Inventors: John S. Lazo; Elizabeth Sharlow; Peter Wipf; Nikhil Tasker; Ettore Rastelli
- Web page: https://patentgrep.com/patent/US20220017534A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides compounds that inhibit protein tyrosine phosphatase, such as protein tyrosine phosphatase 4 A3 (PTP4A3). The disclosure also provides pharmaceutical compositions, uses, and methods of using the compounds, such as in the treatment of cancers.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, selected from the following table:
3
15
9a
9b
9c
9d
9e
9f
9g
9h
9i
9j
9k
9l
9m
9n
9o
9q
9p
NRT- 892-04

### Claim 2 (depends on 1)

A method for treating a subject suffering from cancer, the method comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, ovarian cancer, cervical cancer, lung cancer, liver cancer, stomach cancer, stromal cancer, leukemia, and lymphoma.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the cancer is breast cancer or ovarian cancer.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the cancer is triple negative breast cancer or advanced ovarian cancer.

### Claim 6 (depends on 1)

A method for inhibiting a protein-tyrosine phosphatase in a cell, comprising contacting the cell with a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the protein tyrosine phosphatase is protein tyrosine phosphatase 4A3 (PTP4A3).

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to claim 1.
